<DOC>
	<DOCNO>NCT00631748</DOCNO>
	<brief_summary>This placebo-controlled trial test effectiveness Seroquel XR™ treatment cocaine dependence non-psychotic individual cocaine dependent .</brief_summary>
	<brief_title>Quetiapine Reduction Cocaine Use</brief_title>
	<detailed_description>Cocaine abuse continue epidemic . Co-morbid psychiatric disorder high risk behavior compound morbidity , economic cost , social destruction associate public health crisis . This 12 week , prospective , intent-to-treat , double-blind , randomize , placebo-controlled study Seroquel XR™ versus match placebo , combine cognitive-behavioral group therapy , treatment cocaine dependence non-psychotic individual . We conduct study American Lake ( Tacoma ) Seattle campuses VA Puget Sound Health Care System , recruit veteran non-veteran participant currently use cocaine great Pierce King Counties region . It anticipate 120 subject consent screen study participation 60 subject randomize treatment . After subject provide informed consent , enter 1 week screen phase medical , psychiatric , substance use measure assessment administer determine study eligibility . At baseline , assess cocaine use , cocaine craving , psychiatric symptom , high risk behavior . Also visit , subject randomly assign treatment quetiapine ( target dose 400 mg/day ) placebo . During treatment phase , subject visit clinic week safety monitoring , completion rating questionnaire , UDS 's , participation cognitive-behavioral therapy group . At end study , week 12 , physical examination administer UDS clinical laboratory value obtain . In addition , substance use , psychiatric symptom , high risk behavior assess . To monitor safety evaluate treatment effect , ask participant return follow-up visit week 16 .</detailed_description>
	<mesh_term>Behavior , Addictive</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>1 . Provision write informed consent 2 . Males female age 1865 year 3 . Female subject childbearing potential must use reliable method contraception negative urine human chorionic gonadotropin ( HCG ) test screen baseline visit agree use one follow method birth control : ) oral contraceptive , b ) patch , c ) intrauterine progesterone nonhormonal contraceptive system , ) levonorgestrel implant , e ) medroxyprogesterone acetate contraceptive injection , f ) complete abstinence sexual intercourse 4 . A diagnosis current cocaine dependence ; determine Structured Clinical Interview DSMIVTR Axis I Disorders 69 ( SCIDI/P ) 5 . Has use cocaine within 30 day prior screen 6 . Able understand comply requirement study 7 . Is seek treatment cocaine dependence 8 . Is able provide reliable primary contact phone number able provide reliable alternate contact address phone number , relative close friend 9 . Anticipates life change would preclude study completion 1 . Pregnancy lactation 2 . Currently hospitalize detoxification program 3 . Physiological dependence alcohol , sedative/hypnotic , substance require medical detoxification 4 . Current diagnosis psychotic disorder , include bipolar disorder psychotic feature , determine SCIDI/P clinical interview 5 . Subjects judge investigator psychiatrically unstable , include pose imminent risk suicide danger self others , determine SCIDI/P , CGIS , Hamilton Anxiety Rating Scale ( HAMA ) , Hamilton Rating Scale Depression ( HAMD ) , clinical interview 6 . Known intolerance lack response quetiapine fumarate , judge investigator 7 . Has history neuroleptic malignant syndrome serious adverse reaction antipsychotic medication 8 . Use antipsychotic medication within 30 day precede baseline 9 . Use follow cytochrome P450 3A4 inhibitor 14 day prior baseline include limit : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluoxetine , fluvoxamine , paroxetine , saquinavir 10 . Use follow cytochrome P450 inducer 14 day prior baseline include limit : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoids 11 . Evidence clinically relevant disease ( e.g. , renal , hepatic , gastrointestinal , pulmonary , cardiac , cerebrovascular disease , AIDS , cancer , asthma , neurological neuromuscular disease , seizure disorder , clinically significant abnormal laboratory value ) clinical find judgment investigator could potentially negatively affected study participation could potentially affect study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>cocaine</keyword>
	<keyword>quetiapine fumarate</keyword>
	<keyword>dependence</keyword>
	<keyword>abuse</keyword>
	<keyword>addiction</keyword>
	<keyword>treatment</keyword>
</DOC>